Shows
OncLive® On AirPerioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhDIn this episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, spoke with Petros Grivas, MD, PhD, clinical director of the Genitourinary Cancers Program at Fred Hutchinson Cancer Center and a professor of medicine at the University of Washington School of Medicine, about key updates from the 2025 Genitourinary Cancers Symposium and the evolving treatment paradigm for muscle-invasive bladder cancer (MIBC).2025-03-1223 min
Oncology DecodedNIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder CancerDuring the 2025 ASCO Genitourinary Cancers Symposium, Oncology Decoded held their inaugural podcast with a live filming taking place at the conference. The first episode focused on bladder cancer specifically, neoadjuvant vs adjuvant therapy options and the use of cisplatin vs carboplatin.
Meet the expert panel involved in the discussion:
Manojkumar Bupathi, MD, MS, executive co-chair of Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute; medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and genitourinary cancers;
Benjamin Garmezy, MD, associate director of Genitourinary Research and executive co-chair of Genitourinary Cancer Research Executive Com...2025-03-0433 minOncLive® On AirNeoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MDIn this episode of Oncology Unplugged, a podcast series from OncLive and MedNews Week, podcast host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD, to talk about a pilot trial investigating neoadjuvant accelerated methotrexate, vinblastine,doxorubicin, and cisplatin (aMVAC) plus pembrolizumab (Keytruda) in patients with non-urothelial muscle-invasive bladder cancer, findings from which were presented at the 2025 Genitourinary Cancers Symposium. Dr Grivas is clinical director of the Genitourinary Cancers Program and a professor in the Clinical Research Division at Fred Hutchinson Cancer Center, as well...2025-02-2620 min
Healthcare UnfilteredASCO Updates in GU Oncology With Drs. Rana McKay and Petros GrivasChadi is joined by Drs. Rana McKay and Petros Grivas to discuss the latest genitourinary oncology research updates from the 2024 ASCO Annual Meeting, covering topics such as the prognostic ability of KIM-1 in kidney cancer, patient-reported outcomes from enfortumab vedotin/pembrolizumab treatment, and the final overall survival update from the JAVELIN Renal 101 trial. The conversation also delves into studies on IO/TKI biomarkers, adaptive trials with ctDNA, and the latest findings from trials like KEYNOTE-426, CLEAR, PSMAfore, and SURE-01.
Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/
Watch all Healthcare Unfiltered episodes on...2024-07-2357 min
BackTable UrologyEp. 178 ASCO 2024: Game-Changing GU Oncology Updates in Bladder and Kidney Cancers with Dr. Sumanta Pal and Dr. Petros GrivasStay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros Grivas from Fred Hutchinson Cancer Center and Dr. Sumanta (Monty) Pal from City of Hope.---CHECK OUT OUR SPONSORSiemens Healthineers Theranosticshttps://www.siemens-healthineers.com/en-us/clinical-specialities/theranostics---...2024-07-1656 min
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With PrecisionThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision In support of improving patient care, this activity has been planned and implemented by PVI, PeerView...2024-07-0435 min
PeerView Internal Medicine CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With PrecisionThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision In support of improving patient care, this activity has been planned and implemented by PVI, PeerView...2024-07-0435 min
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With PrecisionThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision In support of improving patient care, this activity has been planned and implemented by PVI, PeerView...2024-07-0435 min
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With PrecisionThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision In support of improving patient care, this activity has been planned and implemented by PVI, PeerView...2024-07-0435 min
PeerView Internal Medicine CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With PrecisionThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision In support of improving patient care, this activity has been planned and implemented by PVI, PeerView...2024-07-0435 min
PeerView Clinical Pharmacology CME/CNE/CPE VideoPetros Grivas, MD, PhD - On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With PrecisionThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision In support of improving patient care, this activity has been planned and implemented by PVI, PeerView...2024-07-0435 min
PeerView Immunology & Transplantation CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With PrecisionThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision In support of improving patient care, this activity has been planned and implemented by PVI, PeerView...2024-07-0435 min
PeerView Immunology & Transplantation CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With PrecisionThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision In support of improving patient care, this activity has been planned and implemented by PVI, PeerView...2024-07-0435 minPeerView Internal Medicine CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative CareThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MBD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care In support of improving patient care, this...2024-06-291h 31PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative CareThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MBD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care In support of improving patient care, this...2024-06-291h 31
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative CareThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MBD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care In support of improving patient care, this...2024-06-291h 31PeerView Immunology & Transplantation CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative CareThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MBD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care In support of improving patient care, this...2024-06-291h 31
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative CareThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MBD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care In support of improving patient care, this...2024-06-291h 31PeerView Immunology & Transplantation CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative CareThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MBD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care In support of improving patient care, this...2024-06-291h 31PeerView Internal Medicine CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative CareThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MBD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care In support of improving patient care, this...2024-06-291h 31PeerView Oncology & Hematology CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative CareThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MBD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care In support of improving patient care, this...2024-06-291h 31
Research To Practice | Oncology VideosUrothelial Bladder Cancer | Oncology Today with Dr Neil Love: Clinical Update on the Current Management of Advanced Urothelial Bladder Cancer'Featuring perspectives from Dr Petros Grivas, including the following topics: Collaboration between urologists and medical oncologists for the management of urothelial bladder cancer (UBC) (0:00) Evolution of treatment modalities for non-muscle-invasive bladder cancer (NMIBC) (11:16) Perspective on recurrence mechanisms of NMIBC (22:21) Potential implications of circulating tumor DNA-based research in the management of bladder cancer (25:27) Importance of collaborative care for patients with bladder cancer (42:02) Frequency of HER2 expression and approach to HER2 testing for metastatic UBC (mUBC); activity of trastuzumab deruxtecan (T-DXd) in HER2-positive solid tumors (46:57) Monitoring and management of T-DXd-associated side effects (1:00:47) Efficacy and ongoing investigation of the HER2...2024-06-181h 23
COR2ED - Oncology Medical ConversationCáncer de próstata: dificultades en la fase preanalítica y pruebas de biomarcadores¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de próstata, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Está escuchando la parte 1 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.
En este episodio, escuchará al especialista en genómica del cáncer genitourinario, el Dr. Alexander Wyatt, y al oncólogo médico, el Dr. Petros Grivas, profundizar sobre las dificultades en la...2024-04-2529 minCOR2ED - Oncology Medical ConversationCâncer de Próstata: Desafios da Fase Pré-Analítica e Teste de BiomarcadoresQuais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de próstata e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está ouvindo a parte 1 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá o especialista em genoma do câncer geniturinário, Dr. Alexander Wyatt, e o oncologista, Dr. Petros Grivas, esclarecerem quais são os desafios d...2024-04-2529 minCOR2ED - Oncology Medical Conversation VideoCâncer de Próstata: Desafios da Fase Pré-Analítica e Teste de BiomarcadoresQuais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de próstata e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está ouvindo a parte 1 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá o especialista em genoma do câncer geniturinário, Dr. Alexander Wyatt, e o oncologista, Dr. Petros Grivas, esclarecerem quais são os desafios d...2024-04-2529 minCOR2ED - Oncology Medical Conversation VideoCáncer de próstata: dificultades en la fase preanalítica y pruebas de biomarcadores¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de próstata, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Está escuchando la parte 1 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.
En este episodio, escuchará al especialista en genómica del cáncer genitourinario, el Dr. Alexander Wyatt, y al oncólogo médico, el Dr. Petros Grivas, profundizar sobre las dificultades en la...2024-04-2529 min
Research To Practice | Oncology VideosMetastatic Urothelial Bladder Cancer | Virtual Case Library: Metastatic Urothelial Bladder CancerFeaturing perspectives from Dr Petros Grivas, Dr Vadim S Koshkin, Dr Kriti Mittal, Dr Mamta Parikh and Dr Scott T Tagawa, including the following topics: First-Line Treatment of Metastatic Urothelial Bladder Cancer (mUBC) — Enfortumab Vedotin/Pembrolizumab Case: A man in his late 80s with recurrent unresectable locally advanced UBC receives first-line enfortumab vedotin and pembrolizumab — Dr Parikh (0:00) Case: A woman in her mid 60s with newly diagnosed mUBC attains an excellent response with first-line enfortumab vedotin and pembrolizumab — Dr Mittal (12:14) Other Approaches to First-Line Treatment of mUBC — Nivolumab/Chemotherapy Case: A man in his mid 70s...2024-03-132h 07
Oncology Learning NetworkSacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 TrialPetros Grivas, MD, PhD, discusses the combination of sacituzumab govetican and pembrolizumab for metastatic urothelial carcinoma in the second-line setting.2024-03-0707 min
Cancer.Net Podcast2023 News and Research in Prostate, Bladder, Kidney, and Testicular CancerYou’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or t...2024-01-2442 minCOR2ED - Oncology Medical Conversation VideoProstate Cancer: Pre-Analytical Phase Challenges and Biomarker TestingWhat are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.
In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.
As the conversation unfolds, the experts explain why it’s so import...2023-12-0629 minCOR2ED - Oncology Medical ConversationProstate Cancer: Pre-Analytical Phase Challenges and Biomarker TestingWhat are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.
In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.
As the conversation unfolds, the experts explain why it’s so import...2023-12-0629 minHealthcare UnfilteredSimplifying the Breakthroughs in Bladder Cancer With Petros GrivasJoin Chadi as he engages with Petros Grivas, MD, PhD, Professor in the Clinical Research division of Fred Hutchinson Cancer Center, to unravel the groundbreaking updates in bladder cancer revealed at the ESMO Congress. Dr. Grivas provides a comprehensive overview, dissecting the advancements in the realms of muscle invasive bladder cancer, non-muscle invasive bladder cancer, and advanced bladder cancer. Delve into the specifics of EV-302, THOR, and many other studies and gain a deeper understanding of the implications these findings may hold for the future of bladder cancer treatment.
Check out Chadi’s website for all Healthcare Unfiltered episodes and ot...2023-11-211h 02
COR2ED Medical EducationProstate Cancer: Pre-Analytical Phase Challenges and Biomarker TestingWhat are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.
In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.
As the conversation unfolds, the experts explain why it’s so import...2023-11-2129 min
COR2ED Medical EducationProstate Cancer: Pre-Analytical Phase Challenges and Biomarker TestingWhat are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.
In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.
As the conversation unfolds, the experts explain why it’s so import...2023-11-2029 min
The UromigosEpisode 277: NMIBC Discussion at #UromigosLive 2023Tom is joined by Sam Chang, Sia Daneshmand, and Petros Grivas to discuss new therapies in non-muscle invasive bladder cancer, including those for BCG-refractory NMIBC and the cretostimogene + pembrolizumab combo for BCG-unresponsive NMIBC.
Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.2023-11-0444 min
Research To Practice | Oncology VideosUrothelial Bladder Cancer | Petros Grivas, MD, PhDInside the Issue: Optimizing the Management of Metastatic Urothelial Bladder Cancer | Faculty Presentation 2: Available Data with, Ongoing Investigation of and Role of Other Novel Strategies for mUBC — Petros Grivas, MD, PhD CME information and select publications2023-08-1055 min
Research To Practice | Oncology VideosUrothelial Bladder Cancer | Inside the Issue: Optimizing the Management of Metastatic Urothelial Bladder CancerFeaturing perspectives from Dr Terence Friedlander and Prof Petros Grivas, including the following topics: Introduction (00:00) First-line treatment of metastatic urothelial bladder cancer (22:39) Second-line therapy and beyond (41:34) CME information and select publications2023-08-101h 02Cancer.Net PodcastGenetic Testing for Bladder Cancer, with Petros Grivas, MD, PhD, and Marianne Dubard-Gault, MD, MSASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, acti...2023-03-2323 min
Oncology Brothers: Practice-Changing Cancer DiscussionsGU ASCO 2023 Highlights with Dr. Petros GrivasDiscussing GU ASCO 2023 Highlights - practice changing / informing studies with Dr. Petros Grivas, Clinical Director of Genitourinary Cancer Program, Professor, Division of Medical Oncology at Fred Hutch Cancer Center.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com2023-02-2218 minThe UromigosEpisode 216: ADCs in Bladder Cancer With Petros Grivas, MD, PhDPetros Grivas, MD, PhD joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer, including enfortumab vedotin (EV) and the results of the drug's EV-301 trial. The combination treatment of EV and pembrolizumab versus chemotherapy alone is also discussed, including the EV-302 trial. Dr. Grivas is a professor in the Division of Medical Oncology at the University of Washington School of Medicine, as well as a physician at Fred Hutch Cancer Center.2023-01-3025 minPeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllGo online to PeerView.com/TCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients who have severe asthma with uncontrolled symptoms and exacerbations are at risk of losing lung function over time. Research and treatment over the past several years have focused on the downstream effectors of allergic and eosinophilic inflammation, including IgE, sputum and blood eosinophils, and IL-4, IL-5, and IL-13. However, the immunology of the epithelial alarmin TSLP provides an opportunity for a novel approach to treat asthma inflammation. In this activity, based on a recent live symposium, experts...2023-01-1353 minPeerView Clinical Pharmacology CME/CNE/CPE VideoPetros Grivas, MD, PhD - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllGo online to PeerView.com/TCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients who have severe asthma with uncontrolled symptoms and exacerbations are at risk of losing lung function over time. Research and treatment over the past several years have focused on the downstream effectors of allergic and eosinophilic inflammation, including IgE, sputum and blood eosinophils, and IL-4, IL-5, and IL-13. However, the immunology of the epithelial alarmin TSLP provides an opportunity for a novel approach to treat asthma inflammation. In this activity, based on a recent live symposium, experts...2023-01-1353 minPeerView Oncology & Hematology CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllGo online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2023-01-071h 01PeerView Internal Medicine CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllGo online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2023-01-071h 01
PeerView Family Medicine & General Practice CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllGo online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2023-01-071h 01PeerView Clinical Pharmacology CME/CNE/CPE VideoPetros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllGo online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2023-01-071h 01PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllGo online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2023-01-071h 01
PeerView Family Medicine & General Practice CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllGo online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2023-01-071h 01PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllGo online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2023-01-071h 01PeerView Internal Medicine CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllGo online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2023-01-071h 01PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllGo online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2023-01-071h 01PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllGo online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2023-01-071h 01
Oncology Learning NetworkEnfortumab Vedotin for Metastatic Urothelial Cancer After Progression on Platinum-Based ChemotherapyPetros Grivas, MD, shares his treatment plan for a patient with metastatic urothelial cancer who has progressed following platinum-based chemotherapy.2022-11-1506 minCancer.Net Podcast2022 Research Round Up: Prostate, Testicular, Bladder, and Kidney CancerASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, acti...2022-06-3049 minPeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease ContinuumGo online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the...2022-06-251h 26PeerView Internal Medicine CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease ContinuumGo online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the...2022-06-251h 26PeerView Internal Medicine CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease ContinuumGo online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the...2022-06-251h 26PeerView Clinical Pharmacology CME/CNE/CPE VideoPetros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease ContinuumGo online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the...2022-06-251h 26PeerView Oncology & Hematology CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease ContinuumGo online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the...2022-06-251h 26PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease ContinuumGo online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the...2022-06-251h 26PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease ContinuumGo online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the...2022-06-251h 26PeerView Family Medicine & General Practice CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease ContinuumGo online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the...2022-06-251h 26PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease ContinuumGo online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the...2022-06-251h 26PeerView Family Medicine & General Practice CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease ContinuumGo online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the...2022-06-251h 26
Oncology Learning NetworkSacituzumab Govitecan Plus Pembrolizumab for Platinum-Refractory Metastatic Urothelial CancerPetros Grivas, MD, from the University of Washington Fred Hutchinson Cancer Research Center, shares results from the TROPHY-U-01 phase 2 trial evaluating the use of sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.2022-06-2208 minPeerView Oncology & Hematology CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic SolutionsGo online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2022-04-071h 28PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic SolutionsGo online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2022-04-071h 28PeerView Clinical Pharmacology CME/CNE/CPE VideoPetros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic SolutionsGo online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2022-04-071h 28PeerView Internal Medicine CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic SolutionsGo online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2022-04-071h 28PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic SolutionsGo online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2022-04-071h 28PeerView Internal Medicine CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic SolutionsGo online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2022-04-071h 28PeerView Family Medicine & General Practice CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic SolutionsGo online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2022-04-071h 28PeerView Family Medicine & General Practice CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic SolutionsGo online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with blad...2022-04-071h 28
VJOncology PodcastNew treatment approaches for advanced or metastatic urothelial carcinomaClinical trials presented at the the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium 2022 have been investigating treatment options for patients with advanced or metastatic UC who are ineligible for or have progressed on platinum-based chemotherapy, in hopes of improving patient prognosis. The LEAP-011 trial explored the addition of the VEGFR inhibitor, lenvatinib, to first-line pembrolizumab for patients ineligible for platinum-based chemotherapy, in hopes of increasing responsiveness to pembrolizumab. The TROPHY-U-01 trial investigated treatment with sacituzumab govitecan for patients with mUC who had progressed on platinum-based chemotherapy and ICIs. The ATLANTIS trial is exploring personalized maintenance treatment...2022-03-1808 min
BIOTalks# Episódio Especial - Pós Simpósio Americano de Tumores Genito-Urinários de 2022 - Câncer UrotelialNesse BIOTalks especial o Dr.Andre Sasse, Dr. Igor Morbeck e Dr. Petros Grivas apresentam e debatem os principais trabalhos em Câncer Urotelial apresentados no Simpósio Americano de Tumores Genito-Urinários de 2022.
Mandem suas críticas, elogios e/ou sugestões: bioeducation@bioeducation.com.br
Siga a BIO no Instagram: @bioeducation
Siga a BIO no Twitter: @OncologyBio
Siga a BIO no Facebook: BIO - Brazilian Information Oncology2022-03-1644 min
The UromigosEpisode 157: ASCO GU 2022 Sasatuzimab and pembrolizumab in bladder cancerPetros Grivas describes the results of this phase 2 trial.2022-02-1817 minPeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based TherapiesGo online to PeerView.com/RPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With multiple novel therapeutics recently approved for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include PD-1/PD-L1–targeting immune checkpoint inhibitors, TKIs targeting fibroblast growth factor receptor (FGFR), and antibody-drug conjugates, into clinical practice. For instance, wh...2022-01-111h 08PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based TherapiesGo online to PeerView.com/RPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With multiple novel therapeutics recently approved for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include PD-1/PD-L1–targeting immune checkpoint inhibitors, TKIs targeting fibroblast growth factor receptor (FGFR), and antibody-drug conjugates, into clinical practice. For instance, wh...2022-01-111h 07PeerView Oncology & Hematology CME/CNE/CPE Video PodcastPetros Grivas, MD, PhD - Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based TherapiesGo online to PeerView.com/RPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With multiple novel therapeutics recently approved for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include PD-1/PD-L1–targeting immune checkpoint inhibitors, TKIs targeting fibroblast growth factor receptor (FGFR), and antibody-drug conjugates, into clinical practice. For instance, wh...2022-01-111h 08PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based TherapiesGo online to PeerView.com/RPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With multiple novel therapeutics recently approved for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include PD-1/PD-L1–targeting immune checkpoint inhibitors, TKIs targeting fibroblast growth factor receptor (FGFR), and antibody-drug conjugates, into clinical practice. For instance, wh...2022-01-111h 07PeerView Clinical Pharmacology CME/CNE/CPE VideoPetros Grivas, MD, PhD - Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based TherapiesGo online to PeerView.com/RPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With multiple novel therapeutics recently approved for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include PD-1/PD-L1–targeting immune checkpoint inhibitors, TKIs targeting fibroblast growth factor receptor (FGFR), and antibody-drug conjugates, into clinical practice. For instance, wh...2022-01-111h 08PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastPetros Grivas, MD, PhD - Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based TherapiesGo online to PeerView.com/RPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With multiple novel therapeutics recently approved for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include PD-1/PD-L1–targeting immune checkpoint inhibitors, TKIs targeting fibroblast growth factor receptor (FGFR), and antibody-drug conjugates, into clinical practice. For instance, wh...2022-01-111h 07VJOncology PodcastKey clinical trial data in urothelial carcinoma at ASCO 2021Chemotherapy is central to the treatment of advanced or metastatic urothelial carcinoma (UC), and platinum-based treatments, like cisplatin, have been the first-line treatment options for many years. To address the limitations of platinum-based chemotherapeutics, additional therapeutics have become available in more recent years for first- and second-line use. Specifically, for patients who are cisplatin-ineligible or those who relapse, immune checkpoint inhibitors, such as avelumab, pembrolizumab, and atezolizumab, targeting the program cell death 1 protein (PD-1) or its ligand (PD-L1), have gained FDA approval. Latest clinical trials have also combined immunotherapy drugs with novel therapies, like the antibody-drug conjugate enfortumab vedotin...2021-09-1019 minCancer.Net Podcast2021 Research Round Up: Prostate, Bladder, Kidney, and Testicular CancersASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be c...2021-06-2351 min
Astra Report | WNTN 1550 AM | Grecian EchoesScience+Mentoring+Networking = WHBA's Summer SchoolThe World Hellenic Biomedical Association - www.WHBA1990.org - has created an amazing opportunity to learn, network and create life long mentorships and friendships. Organizing committee members Eleftheria Ledaki Commercialization Manager, Biopharma, Queen Mary Innovation, UK; Efi Tsouko Post-doctoral research associate, Baylor College of Medicine, USA; Christos Lisgaras Post-doctoral Fellow, New York University and Senior member Dr. Petros Grivas Associate Professor University of Washington, USA discuss the opportunities, challenges and benefits of this unique program.2021-05-2023 minCancer.Net PodcastClinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, KEYNOTE-991ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be c...2021-05-2025 min
Beyond the JournalDr. Petros Grivas, on Adapting to Digital Education and Remote Mentorship Opportunities | BTJ-015Drs. Charu Aggarwal & Jack West host dynamic GU oncology specialist Dr. Petros Grivas as they discuss how research, mentorship, and teaching have adapted to digital platforms in the wake of the pandemic.2021-05-1841 min
Beyond the Journal (Audio)Dr. Petros Grivas, on Adapting to Digital Education and Remote Mentorship Opportunities | BTJ-015Drs. Charu Aggarwal & Jack West host dynamic GU oncology specialist Dr. Petros Grivas as they discuss how research, mentorship, and teaching have adapted to digital platforms in the wake of the pandemic.2021-05-1841 minThe UromigosEpisode 97: Sacituzumab Govitecan in Bladder CancerPetros Grivas discusses the recent accelerated approval and JCO paper data.2021-05-0418 min
CCO Oncology PodcastIncorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the United StatesIn this episode, Petros Grivas, MD, PhD, and Jonathan E. Rosenberg, MD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United States. Topics include:Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapyResults from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapyWhen to consider first-line treatment with immune checkpoint inhibitor monotherapyUtility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapyMonitoring for and managing immune-related adverse events during the COVID-19 pandemic Presenters:Petros Grivas, MD...2021-02-0128 minCancer.Net PodcastHealth Disparities and Cancer Clinical Trials, with Petros Grivas, MD, and Edith P. Mitchell, MD, FACPASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be c...2020-11-3020 min
Healthcare UnfilteredExpert Roundtable: Genitourinary Updates and Top DataChadi facilitates a discussion between three GU oncologists on the latest research and treatment updates in the field. Rana McKay (@DrRanaMcKay), MD, UC San Diego, Petros Grivas (@PGrivasMDPhD), MD, PhD, Fred Hutchinson Cancer Research Center, and Toni Choueiri (@DrChoueiri), MD, Dana-Farber Cancer Institute, debate the practice-changing potential of chosen papers and abstracts presented at ASCO and ESMO, including updated data on the final OS in the PROFOUND trial, context and implications of the JAVELIN trial for bladder cancer, ramifications of the CheckMate 9ER trial for kidney cancer, and more.2020-10-201h 06Cancer.Net PodcastClinical Trials in Genitourinary Cancers: TALAPRO-2, KEYNOTE-905, COSMIC-313ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be c...2020-07-0925 min
GU Cast | Urology PodcastMore bladder cancer!!! With Petros GrivasGU Cast chats to Dr Petros Grivas, GU Medical Oncologist at the University of Washington in Seattle, about the JAVELIN 100 trial which featured in the plenary session at ASCO20 recently. Petros is senior author on this practice-changing study of "switch maintenance" in metastatic bladder cancer, and he joins us today to explain some of the finer details of the study. With audio cameos from Tom Powles, Betsy Plimack, and Vinay Prasad (yikes!). Declan and Renu were also delighted to have Associate Professor Andrew Weickhardt join them in studio today. Andrew is a GU Medical Oncologist at the Olivia-Newton J...2020-06-1436 min
Oncology Learning NetworkNo DFS Benefit With Adjuvant Atezolizumab for High-Risk Urothelial CarcinomaPetros Grivas, MD, PhD, talks about the importance of the IMvigor010 clinical trial, which assessed the use of adjuvant atezolizumab in patients with muscle-invasive urothelial cancer.2020-06-0903 minCancer.Net PodcastClinical Trials in Genitourinary Cancers: KEYLYNK-010, KEYNOTE-866, PDIGREEASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be c...2020-05-0527 minCancer.Net PodcastClinical Trials in Genitourinary Cancers: VISION, INTACT, and PROSPERASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be c...2020-02-1329 minThe UromigosEpisode 2: The Current role of IO in Front-line Advanced Urothelial CancerMatthew Galski and Petros Grivas engage in a discussion with Professor Tom Powles and Dr. Brian Rini about IMVIGOR130.2020-02-1130 min
West Wind (Audio)Dr. Petros Grivas: The Journey from Greece to the US, and the Difficult Question of When to MoveDr. Petros Grivas, genitourinary (GU) cancer expert at the Univ of Washington/Seattle Cancer Care Alliance, describes his path from Greece to the US, his compulsion to deliver, & the challenge of deciding when to stay vs. move on for new opportunities.2020-01-2755 min
The BeaconDr. Petros Grivas: The Journey from Greece to the US, and the Difficult Question of When to MoveDr. Petros Grivas, genitourinary (GU) cancer expert at the Univ of Washington/Seattle Cancer Care Alliance, describes his path from Greece to the US, his compulsion to deliver, & the challenge of deciding when to stay vs. move on for new opportunities.2020-01-2755 min